Last reviewed · How we verify

Cyclosporine A, Tacrolimus, Sirolimus

Central South University · FDA-approved active Small molecule Quality 2/100

Cyclosporine A, Tacrolimus, Sirolimus is a Small molecule drug developed by Central South University. It is currently FDA-approved.

At a glance

Generic nameCyclosporine A, Tacrolimus, Sirolimus
SponsorCentral South University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cyclosporine A, Tacrolimus, Sirolimus

What is Cyclosporine A, Tacrolimus, Sirolimus?

Cyclosporine A, Tacrolimus, Sirolimus is a Small molecule drug developed by Central South University.

Who makes Cyclosporine A, Tacrolimus, Sirolimus?

Cyclosporine A, Tacrolimus, Sirolimus is developed and marketed by Central South University (see full Central South University pipeline at /company/central-south-university).

What development phase is Cyclosporine A, Tacrolimus, Sirolimus in?

Cyclosporine A, Tacrolimus, Sirolimus is FDA-approved (marketed).

Related